Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
John T. Treace is Chief Executive Officer at Treace Medical Concepts. OQRO lists 18 transactions filed with the SEC under this name, the latest on Aug 24, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
18
Companies involved
1
John T. Treace bought shares on the open market in 2022, 2024, 2025 and 2026. Sales in 2 of the 6 years since 2021.
John T. Treace reported 26 open-market purchases and 27 sales since 2021; purchases in 4 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $1.24M12×12 trades | — |
| 2025 | $524K1×1 trade | — |
| 2024 | $3.74M7×7 trades | — |
| 2023 | — | $51K1×1 trade |
| 2022 | $1.73M6×6 trades | — |
| 2021 | — | $98.5M26×26 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
5 buys, median +31.0 pts vs S&P 500, beat it 4 of 5 times.
Average +21.7 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Mar 4, 2025 to Jun 12, 2026, measured from the first close after the filing. Past results, not a forecast.
6 purchases disclosed; 80% of the 5 measured at 90 days finished ahead of the index. $1,000 placed after each of the 5 purchases disclosed since 2025-11-16 would be worth $7.5K today ($5K put in); the same in the S&P 500 (SPY): $5K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Treace Medical ConceptsTMCI
18 disclosures · Mar 2025 – Aug 2026 · 13 bought
Aug 20, 2026Bought~$177Kdisclosed Aug 24
DetailsOfficial recordAug 24, 2026Bought~$48K
DetailsOfficial recordAug 21, 2026Bought~$22Kdisclosed Aug 24
DetailsOfficial recordJun 10, 2026Bought~$59Kdisclosed Jun 12
DetailsOfficial recordJun 11, 2026Bought~$40Kdisclosed Jun 12
DetailsOfficial recordJun 1, 2026Bought~$178K
DetailsOfficial recordMay 28, 2026Bought~$185K
DetailsOfficial recordMay 27, 2026Bought~$143Kdisclosed May 28
DetailsOfficial recordMay 26, 2026Bought~$13Kdisclosed May 28
DetailsOfficial recordMay 14, 2026Bought~$161K
DetailsOfficial recordMay 13, 2026Bought~$121Kdisclosed May 14
DetailsOfficial recordMay 12, 2026Bought~$93Kdisclosed May 14
DetailsOfficial recordMar 8, 20262,062disclosed Mar 12
DetailsOfficial recordMar 10, 20265,021disclosed Mar 12
DetailsOfficial recordJan 22, 2026250Kdisclosed Jan 24
DetailsOfficial recordJan 22, 202614Kdisclosed Jan 24
DetailsOfficial recordJan 10, 202613Kdisclosed Jan 14
DetailsOfficial recordMar 4, 2025Bought~$524K
DetailsOfficial recordAs of the latest filing on , John T. Treace reported holding 7,404,383 shares of Treace Medical Concepts (TMCI), worth about $32.7M at the last close of $4 (Nov 16, 2026). In the last 12 months, John T. Treace bought $1.24M in 12 open-market purchases.
Treace Medical Concepts's proxy statement reports total compensation of $5.41M for John T. Treace for fiscal year 2025, after $6.6M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 6, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Treace Medical Concepts TMCI | 7,404,383 | 7.40M direct | $4 | $32.7M | Aug 24, 2026 |
Is this John T. Treace’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
John T. Treace reported 26 open-market purchases and 27 sales here, 2021 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Aug 24, 2026, John T. Treace reported holding 7,404,383 shares of Treace Medical Concepts (TMCI). At the last close of $4 on Nov 16, 2026, that is about $32.7M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, John T. Treace reported 12 open-market purchases worth $1.24M, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Treace Medical Concepts's proxy statement reports total compensation of $5.41M for John T. Treace for fiscal year 2025, after $6.6M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
John T. Treace bought shares on the open market in 2022, 2024, 2025 and 2026. Sales in 2 of the 6 years since 2021.
In SEC filings since 2021: the latest open-market purchase is from 2026; the latest open-market sale is from 2023.
Treace Medical Concepts (TMCI), from 2021 to 2026: 26 purchases and 27 sales.